American Journal of Obstetrics & Gynecology
Volume 199, Issue 3 , Pages 215-223 , September 2008

The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?

  • Vladimir Nossov, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA
    • ,
  • Malaika Amneus, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA
    • ,
  • Feng Su, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA
    • ,
  • Jennifer Lang, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA
    • ,
  • Jo Marie Tran Janco

      Affiliations

    • Department of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA
    • ,
  • Srinivasa T. Reddy

      Affiliations

    • Atherosclerosis Research Unit, Department of Medicine/Cardiology, University of California, Los Angeles, CA
    • Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA
    • ,
  • Robin Farias-Eisner, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA
    • Stanford University, Stanford, CA
    • Corresponding Author InformationReprints: Robin Farias-Eisner, MD, PhD, UCLA School of Medicine, Department of Obstetrics and Gynecology, 10833 LeConte Ave, Room 24-137 CHS, Los Angeles, CA 90095-1740

Received 18 January 2008 ,Revised 19 March 2008 ,Accepted 4 April 2008.

References 

  1. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65:281–393
  2. Wilson JMG, Jungner G. Principles and practice of screening for disease. WHO Chronicle. 1968;22:473
  3. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993;306:1030–1034
  4. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3:355–366
  5. National Institutes of Health consensus conference. Ovarian cancer (Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer). JAMA. 1995;273:491–497
  6. Jacobs I. Overview—progress in screening for ovarian cancer. In:  Sharp F,  Blackett A,  Berek J,  Bast R editor. Ovarian cancer. Oxford (UK): Isis Medical Media; 1998;
  7. Ozols R, Rubin S, Thomas G, Robboy S. Epithelial ovarian cancer. In:  Hoskins W,  Young R editor. Principles and practice of gynecologic oncology. New York: Williams and Wilkins; 2001;
  8. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2:275–285
  9. Nustad K, Bast RC, Brien TJ, et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop (International Society for Oncodevelopmental Biology and Medicine). Tumour Biol. 1996;17:196–219
  10. Lloyd KO, Yin BW, Kudryashov V. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): Identification as a mucin-type molecule. Int J Cancer. 1997;71:842–850
  11. Bast RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–887
  12. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: Reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem. 1993;39:2509–2513
  13. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984;50:765–769
  14. Hogdall EV, Christensen L, Kjaer SK, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients (From The Danish “MALOVA” Ovarian Cancer Study). Gynecol Oncol. 2007;104:508–515
  15. Zurawski VR, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer. Int J Cancer. 1988;42:677–680
  16. Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 1993;269:1123–1126
  17. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003;21:206s–210s
  18. Valentin L, Skoog L, Epstein E. Frequency and type of adnexal lesions in autopsy material from postmenopausal women: Ultrasound study with histological correlation. Ultrasound Obstet Gynecol. 2003;22:284–289
  19. Bailey CL, Ueland FR, Land GL, et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol. 1998;69:3–7
  20. Levine D, Gosink BB, Wolf SI, Feldesman MR, Pretorius DH. Simple adnexal cysts: The natural history in postmenopausal women. Radiology. 1992;184:653–659
  21. Menon U, Talaat A, Rosenthal AN, et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG. 2000;107:165–169
  22. Osmers RG, Osmers M, von Maydell B, Wagner B, Kuhn W. Preoperative evaluation of ovarian tumors in the premenopause by transvaginosonography. Am J Obstet Gynecol. 1996;175:428–434
  23. Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Nagell JR. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol. 2003;102:594–599
  24. Granberg S, Wikland M, Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: Criteria to be used for ultrasound evaluation. Gynecol Oncol. 1989;35:139–144
  25. Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni AA. Transvaginal ultrasonographic characterization of ovarian masses: Comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol. 1997;10:192–197
  26. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol. 1994;170:81–85
  27. Mol BW, Boll D, De Kanter M, et al. Distinguishing the benign and malignant adnexal mass: An external validation of prognostic models. Gynecol Oncol. 2001;80:162–167
  28. Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: Evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol. 1991;78:70–76
  29. Timmerman D, Bourne TH, Tailor A, et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: The development of a new logistic regression model. Am J Obstet Gynecol. 1999;181:57–65
  30. Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, van Nagell JR. Preoperative differentiation of malignant from benign ovarian tumors: The efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol. 2003;91:46–50
  31. Kurjak A, Shalan H, Kupesic S, et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med. 1994;13:295–301
  32. Vuento MH, Pirhonen JP, Makinen JI, Laippala PJ, Gronroos M, Salmi TA. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer. 1995;76:1214–1218
  33. Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ. 1993;306:1025–1029
  34. Parkes CA, Smith D, Wald NJ, Bourne TH. Feasibility study of a randomised trial of ovarian cancer screening among the general population. J Med Screen. 1994;1:209–214
  35. Stein SM, Laifer-Narin S, Johnson MB, et al. Differentiation of benign and malignant adnexal masses: Relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol. 1995;164:381–386
  36. Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: The contribution of Doppler ultrasound. Ultrasound Obstet Gynecol. 1999;14:338–347
  37. Guerriero S, Ajossa S, Melis G. Is three-dimensional power Doppler ultrasound better than two-dimensional power Doppler?. Gynecol Oncol. 2002;84:352–353
  38. Testa AC, Ajossa S, Ferrandina G, et al. Does quantitative analysis of three-dimensional power Doppler angiography have a role in the diagnosis of malignant pelvic solid tumors? (A preliminary study). Ultrasound Obstet Gynecol. 2005;26:67–72
  39. Guerriero S, Alcazar JL, Ajossa S, et al. Comparison of conventional color Doppler imaging and power Doppler imaging for the diagnosis of ovarian cancer: Results of a European study. Gynecol Oncol. 2001;83:299–304
  40. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: A pilot randomised controlled trial. Lancet. 1999;353:1207–1210
  41. Skates SJ, Pauler DK, Jacobs IJ. Screening based on the risk of ovarian cancer calculation from bayesian hierarchical change point and mixture models of longitudinal markers. J Am Stat Assoc. 2001;96:429–439
  42. Bosse K, Rhiem K, Wappenschmidt B, et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study. Gynecol Oncol. 2006;103:1077–1082
  43. Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer. 2006;94:814–819
  44. Nossov V, Shapiro A, Li A, Leuchter R, Karlan B, Cass I. Jewish women are at higher risk for primary peritoneal carcinoma. Presented at the Annual Meeting of the Society for Gynecologic Oncology, 2007. San Diego, CA. March 2007.
  45. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1:683–695
  46. Gray JW, Suzuki S, Kuo WL, et al. Specific keynote: Genome copy number abnormalities in ovarian cancer. Gynecol Oncol. 2003;88:S16–S21discussion S22-4
  47. Suzuki S, Moore DH, Ginzinger DG, et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res. 2000;60:5382–5385
  48. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21:99–102
  49. Wulfkuhle JD, Aquino JA, Calvert VS, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics. 2003;3:2085–2090
  50. Wong AS, Kim SO, Leung PC, Auersperg N, Pelech SL. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol. 2001;82:305–311
  51. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol Cell Proteomics. 2004;3:311–326
  52. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–3700
  53. Urban N. Specific keynote: Ovarian cancer risk assessment and the potential for early detection. Gynecol Oncol. 2003;88:S75–S79discussion S80-3
  54. Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet Gynecol. 1993;82:946–950
  55. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719–723
  56. Xu FJ, Ramakrishnan S, Daly L, et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol. 1991;165:1356–1362
  57. Chechlinska M, Kaminska J, Markowska J, Kramar A, Steffen J. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. Int J Biol Markers. 2007;22:172–180
  58. Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol. 1995;59:111–116
  59. Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol. 1999;73:56–61
  60. Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY. Ovarian cancer tumor marker behavior in asymptomatic healthy women: Implications for screening. Cancer Epidemiol Biomarkers Prev. 2000;9:1107–1111
  61. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004;10:3291–3300
  62. Zhang Z, Bast RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882–5890
  63. Leiser A, Visintin I, Alvero A, et al. Novel serum test for the early detection of ovarian cancer. Gynecol Oncol. 2007;104:S2–S35
  64. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14:1065–1072
  65. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002;287:1671–1679
  66. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7:4060–4066
  67. Schorge JO, Drake RD, Lee H, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res. 2004;10:3474–3478
  68. Ye B, Cramer DW, Skates SJ, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 2003;9:2904–2911
  69. Rai AJ, Zhang Z, Rosenzweig J, et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med. 2002;126:1518–1526
  70. Yu JK, Zheng S, Tang Y, Li L. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J Zhejiang Univ Sci B. 2005;6:227–231
  71. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–577
  72. Conrads TP, Fusaro VA, Ross S, et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer. 2004;11:163–178
  73. Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A. 2003;100:12343–12348
  74. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005;5:4589–4596
  75. Mahlck CG, Grankvist K. Plasma prealbumin in women with epithelial ovarian carcinoma. Gynecol Obstet Invest. 1994;37:135–140
  76. Kuesel AC, Kroft T, Prefontaine M, Smith IC. Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. Int J Cancer. 1992;52:341–346
  77. Gadomska H, Grzechocinska B, Janecki J, Nowicka G, Powolny M, Marianowski L. Serum lipids concentration in women with benign and malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol. 2005;120:87–90
  78. Dionyssiou-Asteriou A, Papastamatiou M, Vatalas IA, Bastounis E. Serum apolipoprotein AI levels in atherosclerotic and diabetic patients. Eur J Vasc Endovasc Surg. 2002;24:161–165
  79. Feinleib M. On a possible inverse relationship between serum cholesterol and cancer mortality. Am J Epidemiol. 1981;114:5–10
  80. Sorlie PD, Fienleib M. The serum cholesterol-cancer relationship: an analysis of time trends in the Framingham Study. J Natl Cancer Inst. 1982;69:989–996
  81. Williams RR, Sorlie PD, Feinleib M, McNamara PM, Kannel WB, Dawber TR. Cancer incidence by levels of cholesterol. JAMA. 1981;245:247–252
  82. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1990;9:515–540
  83. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239–267
  84. Cvetkovic D, Williams SJ, Hamilton TC. Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. Clin Cancer Res. 2003;9:1013–1020
  85. Corti MC, Gaziano M, Hennekens CH. Iron status and risk of cardiovascular disease. Ann Epidemiol. 1997;7:62–68
  86. Dumaswala UJ, Wilson MJ, Wu YL, et al. Glutathione loading prevents free radical injury in red blood cells after storage. Free Radic Res. 2000;33:517–529
  87. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer. 1996;32A:30–38
  88. Kang DH. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues. 2002;13:540–549
  89. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266:37–56
  90. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1–40
  91. Su F, Lang J, Kumar A, et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights. 2007;269–375
  92. Diamandis EP. Point: Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics?. Clin Chem. 2003;49:1272–1275
  93. Chan K, Lucas D, Hise D. Analysis of the human serum proteome. Clinical Proteomics. 2004;101–226
  94. Benjapibal M, Neungton C. Pre-operative prediction of serum CA125 level in women with ovarian masses. J Med Assoc Thai. 2007;90:1986–1991
  95. Kupesic S, Plavsic BM. Early ovarian cancer: 3-D power Doppler. Abdom Imaging. 2006;31:613–619

PII: S0002-9378(08)00400-6

doi: 10.1016/j.ajog.2008.04.009

American Journal of Obstetrics & Gynecology
Volume 199, Issue 3 , Pages 215-223 , September 2008

Article Tools